D. V. Von Hoff

Publications717
h-index99
Citations54,942
Highly Influential Citations1,443
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • R. Hruban
  • 1,308 Publications • 153,060 Citations
  • A. Maitra
  • 856 Publications • 80,155 Citations
  • R. Ramanathan
  • 370 Publications • 22,096 Citations
  • Haiyong Han
  • 152 Publications • 4,973 Citations
  • Publications
  • Influence
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
TLDR
It is demonstrated that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer and confers a modest survival advantage over treatment with5-FU.
View on PubMed
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.
TLDR
In patients with metastatic pancreatic adenocarcinoma, nab-paclitaxel plus gemcitabine significantly improved overall survival, progression-free survival, and response rate, but rates of peripheral neuropathy and myelosuppression were increased.
View on PubMed
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma.
View on PubMed
Risk factors for doxorubicin-induced congestive heart failure.
TLDR
There was a continuum of increasing risk as the cumulative amount of administered drug increased, and a weekly dose schedule of doxorubicin was associated with a significantly lower incidence of congestive heart failure than was the usually employed every 3-week schedule.
View on PubMed
Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.
TLDR
GDC-0449, an orally active small molecule that targets the hedgehog pathway, appears to have antitumor activity in locally advanced or metastatic basal-cell carcinoma.
View on PubMed
Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial.
TLDR
The regimen of nab-paclitaxel plus gemcitabine has tolerable adverse effects with substantial antitumor activity, warranting phase III evaluation.
View on PubMed
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
TLDR
The recommended dose for disease-directed studies of OSI-774 administered orally on a daily, continuous, uninterrupted schedule is 150 mg/d, and several patients with epidermoid malignancies demonstrated either antitumor activity or relatively long periods of stable disease.
View on PubMed
Hypersensitivity reactions from taxol.
TLDR
Hypersensitivity reactions to taxol have been one of the toxicities observed with administration of this drug and guidelines are provided to prevent or minimize such toxicity and treat reactions if they still occur.
View on PubMed
Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
TLDR
It is possible to identify molecular targets in patients' tumors from nine different centers across the United States and in 27% of patients, the MP approach resulted in a longer PFS on an MP-suggested regimen than on the regimen on which the patient had just experienced progression.
View on PubMed
Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.
TLDR
A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies was treated with a novel hedgehog pathway inhibitor, GDC-0449; treatment resulted in rapid (although transient) regression of the tumor and reduction of symptoms.
View on PubMed
...
...